Table 5 Atrial fibrillation-related real-world costs (€) of anticoagulation therapies during the one-year follow-up period. The CIs for the cost difference were based normal distributions

AF-related total cost for healthcare

805.2 ± 1118.7

766.3–844.1

927.3 ± 1150.9

849.0–1005.6

− 122.1

0.006

AF-related total cost for patient

296.7 ± 256.3

287.8–305.6

406.5 ± 132.8

397.5–415.5

−109.8

< 0.001

AF-related total cost (patient + healthcare)

1102.0 ± 1272.2

1057.7–1146.3

1333.8 ± 1250.8

1248.7–1418.9

−231.8

< 0.001

 Patient’s time and travel cost

195.6 ± 221.8

187.9–203.3

17.5 ± 61.5

13.3–21.7

178.1

< 0.001

 Patient’s time cost

79.5 ± 84.4

76.6–82.4

3.3 ± 11.2

2.5–4.1

76.2

< 0.001

 Patient’s travel cost

118.2 ± 168.1

112.3–124.1

14.3 ± 52.4

10.7–17.9

103.9

< 0.001

 Healthcare fees for patient

74.0 ± 155.0

68.6–79.4

29.2 ± 88.0

23.2–35.2

44.8

< 0.001

 Drug cost for patient

27.0 ± 0.0

27.0–27.0

359.8 ± 10.4

359.1–360.5

− 332.8

< 0.001

 INR monitoring cost

519.2 ± 296.2

508.9–529.5

4.3 ± 14.1

3.3–5.3

514.9

< 0.001

 Primary healthcare visit costs

12.7 ± 51.7

10.9–14.5

16.6 ± 47.5

13.4–19.8

−3.9

0.042

 Specialised healthcare visit costs

61.1 ± 303.9

50.5–71.7

100.3 ± 608.5

58.9–141.7

−39.2

0.072

 Ward costs in primary healthcare

12.2 ± 130.2

10.9–14.5

13.9 ± 122.4

5.6–22.2

−1.7

0.731

 Ward costs in specialised healthcare

78.6 ± 706.7

54.0–103.2

88.4 ± 781.0

35.2–141.6

−9.8

0.743

 Drug cost for society

18.0 ± 0.0

18.0–18.0

668.2 ± 19.4

666.9–669.5

− 650.2

< 0.001

 Kela’s travel cost for society

99.3 ± 305.4

88.7–109.9

26.5 ± 110.8

19.0–34.0

72.8

< 0.001